RapidEye/iStock via Getty Images Pyxis Oncology (NASDAQ:PYXS) is an antibody and antibody-drug conjugate (ADC) developer that I covered back in March. At that time, I rated it a hold, as the company had the funds it needed to run its trials, but there was no near-term clinical catalyst. This article looks at updates from the company and the near-term catalyst of PYX-201 data. The clinical timeline While I lamented slippage to the timeline of clinical readouts in my previous article on PYXS, the timeline for ...

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on Septem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40881 | --- | --- | |----------------------------------------------------------------------------|------------------------------------------| | | | | | | | Pyxis On ...

Financial Position - As of June 30, 2024, Pyxis Oncology had cash and cash equivalents totaling $157.2 million, expected to fund operations into the second half of 2026[6]. - Total assets as of June 30, 2024, were $208.4 million, an increase from $173.7 million at the end of 2023[11]. - The outstanding number of shares of common stock as of August 14, 2024, was 58,942,243[7]. Revenue and Expenses - Total revenues for the six months ended June 30, 2024, were $16.1 million, primarily from royalty revenues and the sale of royalty rights[10]. - Research and development expenses for Q2 2024 were $13.9 million, up from $11.4 million in Q2 2023, primarily due to increased clinical trial-related expenses[6]. - General and administrative expenses decreased to $6.1 million in Q2 2024 from $6.7 million in Q2 2023[7]. - The net loss for Q2 2024 was $17.3 million, or ($0.29) per common share, compared to a net loss of $15.9 million, or ($0.41) per common share, in Q2 2023[7]. Clinical Trials - A total of 72 subjects have been dosed in the ongoing Phase 1 trial of PYX-201, focusing on various difficult-to-treat cancers[3]. - The company expects to announce preliminary data from the Phase 1 trial of PYX-201 in fall 2024, including efficacy and safety results[4]. - PYX-106, another clinical candidate, has dosed 33 subjects in its Phase 1 trial, with preliminary data expected by year-end 2024[5].

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for mono and combination therapies. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple t ...

Core Insights - Pyxis Oncology, Inc. is focused on developing next-generation therapeutics for difficult-to-treat cancers [5] - The company has granted restricted stock units and stock options to five newly hired employees as part of its 2022 Inducement Plan [1][2] Employee Compensation - A total of 89,530 restricted stock units and 111,913 stock options were granted to new employees [1] - The stock options have a ten-year term with an exercise price of $3.31, which is the closing price of the company's common stock on June 28, 2024 [2] - The vesting schedule for the stock options includes 25% vesting on the first anniversary and the remaining shares vesting monthly over the following 36 months [2] Company Overview - Pyxis Oncology is a clinical-stage company developing therapeutics such as PYX-201 and PYX-106, targeting solid tumors [5] - The company's therapeutic candidates aim to directly kill tumor cells and address cancer-related pathologies that contribute to proliferation and immune evasion [5] - Pyxis Oncology employs novel strategies in its antibody-drug conjugate and immuno-oncology programs to target a wide range of solid tumors resistant to current treatments [5]

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) ...

Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 77.78%. A quarter ago, it was expected that this company would post a loss of $0.49 per share when it actually produced a loss of $0.33, delivering a surprise of 32.65%. Over the last four quarters, the company has s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40881 Pyxis Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 83-1160910 | | --- | --- | | (State or other jurisdiction of incorpo ...

Exhibit 99.1 Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024 May 14, 2024 PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Dr. Sullivan added, "We plan to dose an additional 16 patients with a focus on five tumor types of interest based on an assessment of factors including immunohistochemistry target expression, stromal volume, unmet medical need, and clinical judgment. Patient recruitment at these dose levels focuses on head and neck squamous c ...